Novo Nordisk's weekly injection diabetes drug Kyinsu has been approved in the European Union

Novo Nordisk's weekly injectable diabetes medication has been approved by the European Union, providing patients with another treatment option. The European Medicines Agency's drug review panel recommended the approval of Kyinsu for the treatment of patients with type 2 diabetes. This combination injectable, consisting of insulin and semaglutide (the active ingredient in Novo Nordisk's bestselling weight loss drug Ozempic), is also known as IcoSema. Trials of the drug have shown that it helps patients with type 2 diabetes better control their weight and lower blood sugar, outperforming daily insulin injections. This medication is also beneficial for those who cannot control their diabetes through daily insulin injections. The long-acting insulin component of the drug was previously rejected for approval by the U.S. Food and Drug Administration, as the agency requested more detailed information regarding the manufacturing process and indications for type 1 diabetes